Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway for smooth muscle (SM) control in other urogenital tracts (UGTs) make PDE5-Is promi...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000795/ |